Table 2.
Cox proportional hazards model of baseline prognosticators for overall survival in patients with early stage HCC after radiofrequency ablation.
| Factors | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age, per 1 year increase | 1.02 (0.98–1.05) | 0.323 | ||
| Gender, male vs female | 1.07 (0.59–1.96) | 0.824 | ||
| BMI, per kg/m2 increase | 0.62 (0.34–1.14) | 0.126 | ||
| Diabetes mellitus, yes or no | 1.44 (0.80–2.58) | 0.224 | ||
| ESRD, yes or no | 3.50 (1.47–8.31) | 0.005 | 3.60 (1.48–8.76) | 0.005 |
| CSPH, yes or no | 2.26 (0.88–5.79) | 0.091 | ||
| Tumor number, solitary vs multiple | 0.84 (0.43–1.64) | 0.612 | ||
| Tumor stage, I vs II | 0.85 (0.43–1.68) | 0.646 | ||
| Tumor size, ≥3cm vs <3cm | 1.79 (0.96–3.32) | 0.066 | ||
| HBsAg positive, yes or no | 1.64 (0.89–3.02) | 0.113 | ||
| NA before RFA, yes or no* | 1.28 (0.47–3.44) | 0.631 | ||
| NA after RFA, yes or no* | 1.20 (0.44–3.33) | 0.720 | ||
| Anti-HCV positive, yes or no | 0.88 (0.46–1.70) | 0.710 | ||
| IFN before RFA, yes or no** | 0.68 (0.29–1.58) | 0.368 | ||
| IFN or DAA after RFA, yes or no** | 0.05 (0.01–0.36) | 0.003 | ||
| AFP(ng/ml), ≥200 vs <200 | 3.50 (1.47–8.31) | 0.005 | 4.61 (1.75–12.13) | 0.002 |
| Child-Pugh class A vs B or C | 0.36 (0.20–0.66) | 0.001 | ||
| Ascites, yes or no | 4.67 (2.48–8.80) | 0.001 | ||
| NLR ≥2.5 vs <2.5 | 2.31 (1.28–4.17) | 0.006 | 1.94 (1.05–3.59) | 0.034 |
| PLR ≥100 vs <100 | 1.30 (0.70–2.41) | 0.404 | ||
| PNI ≥40 vs <40 | 0.42 (0.23–0.76) | 0.005 | 0.38 (0.20–0.72) | 0.003 |
| ALBI grade, 1 vs 2/3 | 0.42 (0.20–0.87) | 0.020 | ||
| FIB-4, per 1 increase | 1.02 (0.95–1.08) | 0.659 | ||
*in 32 HBsAg positive pa lgtients; **in 88 Anti-HCV positive patients.
HR, hazard ratio; CI, confidence interval; BMI, body mass index; ESRD, end-stage renal disease; CSPH, clinically significant portal hypertension; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue; HCV, hepatitis C virus; IFN, interferon; DAA, direct acting antivirals; AFP, α-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; ALBI, albumin-bilirubin; Fib-4, Fibrosis-4.